Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Stock Has Consensus Target Price of $56.38

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has earned a consensus rating of “Moderate Buy” from the twelve research firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $56.38.

Several research analysts recently issued reports on IMCR shares. JPMorgan Chase & Co. assumed coverage on Immunocore in a research report on Friday, August 21st. They set an “overweight” rating and a $50.00 target price on the stock. Zacks Research downgraded Immunocore from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 3rd. Mizuho boosted their price target on Immunocore from $34.00 to $35.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Morgan Stanley set a $43.00 price objective on shares of Immunocore in a report on Friday, August 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research report on Monday, July 13th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Engineers Gate Manager LP raised its holdings in shares of Immunocore by 334.3% in the second quarter. Engineers Gate Manager LP now owns 60,327 shares of the company’s stock worth $1,915,000 after buying an additional 46,435 shares during the last quarter. denkapparat Operations GmbH purchased a new stake in shares of Immunocore during the second quarter valued at $209,000. Braidwell LP purchased a new stake in shares of Immunocore during the second quarter valued at $16,552,000. Headlands Technologies LLC acquired a new position in shares of Immunocore in the 2nd quarter valued at $290,000. Finally, Public Employees Retirement System of Ohio purchased a new position in Immunocore in the 2nd quarter worth $2,145,000. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore Price Performance

NASDAQ IMCR opened at $31.29 on Tuesday. The firm’s fifty day simple moving average is $34.52 and its two-hundred day simple moving average is $31.76. The firm has a market capitalization of $1.61 billion, a P/E ratio of -84.57 and a beta of 0.74. The company has a current ratio of 4.47, a quick ratio of 4.44 and a debt-to-equity ratio of 0.94. Immunocore has a 12-month low of $27.56 and a 12-month high of $40.71.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Immunocore had a negative net margin of 4.20% and a negative return on equity of 4.54%. Analysts forecast that Immunocore will post 0.06 EPS for the current fiscal year.

About Immunocore

Immunocore Holdings plc is a biotechnology company that develops T-cell receptor (TCR) therapies designed to direct the immune system against cancer and other serious diseases. Its ImmTAC platform uses engineered TCRs to recognize disease-related peptides presented on the surface of cells and recruit T cells to destroy targeted cells.

The company’s lead product is KIMMTRAK (tebentafusp-tebn), an ImmTAC therapy approved in the United States, European Union and other markets for the treatment of unresectable or metastatic uveal melanoma in certain patients.